NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders meeting, Axel-Sven Malkomes and Donald Bergstrom, M.D., Ph.D., have been appointed as Directors of the Companys Board of Directors, effective immediately.
We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board. They are both seasoned leaders within the healthcare industry, who bring decades of experience in both the healthcare and financial services sectors to Cellectis. We are confident they will provide meaningful and valued perspectives as we continue to progress toward becoming one of the few end-to-end cell and gene therapy companies, said Dr. Andr Choulika, Chief Executive Officer.
Donald A Bergstrom, M.D., Ph.D.
As of today, Dr. Bergstrom will serve as Director of Cellectis Board. Previously, Donald A Bergstrom, M.D., Ph.D., was appointed as a Board Observer on the Companys Board of Directors on November 4, 2021.
Dr. Bergstrom currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company. He brings with him over 15 years of experience in the biopharmaceutical and medical industries.
Prior to his tenure at Relay Therapeutics, Dr. Bergstrom was Chief Medical Officer at Mersana Therapeutics, where he led the advancement of two products based on Mersanas proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Prior to Mersana, he was Global Head of Translational and Experimental Medicine at Sanofi Oncology. At Sanofi, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as Oncology Franchise Lead, Experimental Medicine. Dr. Bergstrom holds an M.D. from the University of Washington, Seattle, and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed his post-doctoral training. He was a resident in clinical pathology at the University of Washington.
Axel-Sven Malkomes
Axel-Sven Malkomes served as Chief Financial Officer & Chief Business Officer at Medigene AG, a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, until March 31st, 2022. He brings with him over 25 years of experience in the healthcare sector.
Previous to his tenure at Medigene, Mr. Malkomes served as Vice Chairman & Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Prior to joiningBarclays, he was Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Socit Gnrale.
On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK listedprivate equity firm 3iplc.as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as Head of Strategic Planning as well as Head ofMergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business.
During his international management career, Mr. Malkomes gained extensive knowledge of the pharmaceutical industry.
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases. Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit http://www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For further information, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300
Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577
Forward-looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as anticipate, believe, intend, expect, plan, scheduled, could, would and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Attachment
Read the original here:
- Stem Cell Banking Market Size To Surpass USD 19.29 Billion By 2030, Exhibiting A CAGR Of 13.69% As Revealed... - WhaTech - March 18th, 2024
- Stem Cell Banking Market Size, Share, Competitive Landscape and Trend Analysis and Industry Forecast, - EIN News - January 18th, 2024
- Stem Cell Banking Market Predicted to Witness Steady Growth ... - Digital Journal - September 8th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR 15.6% - EIN News - September 7th, 2023
- Stem Cell Banking Market Trends: Industry Analysis and Growth Projections Through 2030 - Benzinga - September 3rd, 2023
- Stem Cell Banking Market Report: Analysis of Effective Business ... - Digital Journal - August 30th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR of 15.6% - openPR - July 19th, 2023
- Stem Cell Banking Market expected to reach USD 16,474.30 million by 2029 - openPR - July 8th, 2023
- Global Stem Cell Banking Market is expected to reach a market size of ~US$ 15 billion by 2028: Ken Research - openPR - June 8th, 2023
- Stem Cell Banking Market: CAGR of 8.2% and Market Valuation ... - KaleidoScot - June 8th, 2023
- Cord Stem Cell Banking Market Size to Surpass USD 45.64 Billion with CAGR of 22% by 2030 - openPR - June 4th, 2023
- Forecasting the Future of the Stem Cell Banking Market : Trends and Insights | CCBC, Crioestaminal, Esperite, - openPR - April 29th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | Current Trends and Industry Analysis - EIN News - April 27th, 2023
- Stem Cell Banking Offers Health And Investment Opportunity - ValueWalk - April 21st, 2023
- Stem Cell Banking Offers Health and Investment Opportunity ... - SavingAdvice.com - April 19th, 2023
- Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR - April 12th, 2023
- Stem Cell Banking Market Size Expected to Reach USD 16,474.30 Million by 2029 with 16.1% CAGR - openPR - March 29th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- Stem Cell Banking Market Top-Players And Qualitative Future ... - Digital Journal - February 13th, 2023
- Global Stem Cell Banking Market Overview, Regional Analysis, Market Share and Competitive Analysis - openPR - February 4th, 2023
- What is Stem Cell Banking? | Stem Cell Preservation in India | Stem ... - January 7th, 2023
- Stem Cell & Cord Blood Banking Dubai, UAE - CellSave Arabia - January 5th, 2023
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - January 5th, 2023
- Private stem cell banking & genetic screening | Future Health Biobank - December 24th, 2022
- Stem Cell Banking Outsourcing Market is anticipated to expand at a ... - Digital Journal - December 20th, 2022
- Stem Cell Banking market size is estimated to be worth USD 1789 million in 2021 and is forecast to a readjuste - openPR - December 15th, 2022
- Stem Cell Banking Market To Reach USD 2927.2 Million By 2028 With A CAGR of 7.2% | Valuates Reports - Yahoo Finance - December 11th, 2022
- Stem Cell Banking Market registering a CAGR of 16.1% by forecast 2029 - openPR - December 1st, 2022
- Stem Cell Banking Industry 2022 - 2028 Market Analysis by Regions, Types and Application - openPR - November 6th, 2022
- Stem Cell Banking & Therapy In India | ReeLabs - October 25th, 2022
- Worldwide Stem Cell Banking Industry to 2027 - Rising Number of Fatal ... - October 25th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 25th, 2022
- Placental Stem Cell Therapy Market - Know the Latest Profit Sources of the Industry - openPR - October 18th, 2022
- Outlook on the Cord Blood Banking Services Global Market to 2027 - by Component, Storage Services, Application and Region - GlobeNewswire - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 12th, 2022
- News from the world of Education: October 12, 2022 - The Hindu - October 12th, 2022
- Stemcord | Home - October 9th, 2022
- Global Cord Blood Banking Market - Competition Forecast and Opportunities, 2027 - Yahoo Finance - October 9th, 2022
- Cell Banking Outsourcing Market Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2031 The Colby Echo News - The Colby Echo... - October 4th, 2022
- Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Business Wire - September 29th, 2022
- Biobanking Market Size to Surge at the CAGR of 5.9% from 2022-2031 - Digital Journal - September 19th, 2022
- Stem Cell Banking Solutions | Hope Biosciences - September 19th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 17th, 2022
- Stem Cell Banking Market to Witness Massive Growth by 2029 | CCBC, CBR - Fighting Hawks Magazine - Fighting Hawks Magazine - September 15th, 2022
- Stem Cell Banking Market Analysis, 2031: Advancements in the field of Regenerative Medicine - BioSpace - September 15th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 15th, 2022
- Cord Blood Banking Services Market Size Estimated to Reach $3.6 Billion By 2027 at a CAGR of 11.8% During Forecast Period 2022-2027. - Digital Journal - August 30th, 2022
- Applied StemCell expands manufacturing facility to support cell and gene therapies - BioPharma-Reporter.com - August 30th, 2022
- What is Cord Blood Banking? - Benzinga - August 30th, 2022
- Vita 34 records moderate upward trend in the second quarter - PharmiWeb.com - August 30th, 2022
- dental stem cell banking - National Dental Pulp Laboratory - August 29th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 24th, 2022
- Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells - Nature.com - August 12th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 10th, 2022
- Building a healthtech industry in Europe to serve patients - Labiotech.eu - August 9th, 2022
- Cell & Gene Therapy Manufacturing Services Market Research Report : With Healthy CAGR 7.8% : Will Reach USD 56.7 Billion by 2028 - Digital Journal - August 6th, 2022
- Oldest patient yet cured of HIV after stem cell transplant researchers - Global Banking And Finance Review - July 28th, 2022
- Stem Cell Banking Market Size to Accelerate at a Rapid CAGR of 16.1% from 2022 to 2029 - Digital Journal - July 25th, 2022
- Global Stem Cell Banking Outsourcing Market 2022 Trend Analysis, Growth Status, Revenue Expectation to 2028 This Is Ardee - This Is Ardee - July 19th, 2022
- Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million - Business Wire - July 14th, 2022
- Stem Cell Banking Market Detailed In New Research Report 2022 | Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH... - July 12th, 2022
- Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM - Yahoo Finance - July 7th, 2022
- Cord Stem Cell Banking Market Size, Global Industry, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by DBMR... - July 7th, 2022
- Allogenic Stem Cell Therapy Market Research by Size, Share, Trends, Business Opportunities and Top Manufacture and Forecast by 2027 Designer Women -... - July 7th, 2022
- expert reaction to study that uses freeze-dried somatic cells to produce cloned mice - Science Media Centre - July 5th, 2022
- South Korea Stem Cell Banking Market Report 2022 - ResearchAndMarkets.com - Business Wire - July 4th, 2022
- NorthX jumps into cell therapies with help from Alder - Bioprocess Insider - BioProcess Insider - June 28th, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - PharmiWeb.com - June 26th, 2022
- Cord Stem Cell Banking Market Size, Share, Application, Trends, Growth, Opportunities and Worldwide Forecast Designer Women - Designer Women - June 24th, 2022
- Indian Optical Brightening Agents Market To Be Driven By Rising Manufacturing Operations In The Forecast Period Of 2022-2027 Designer Women -... - June 22nd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - Yahoo Finance UK - June 22nd, 2022
- Stem Cell Banking Market Global Outlook on Key Growth Trends, Factors and Forecast 2028: Cord Blood Registry (CBR) Systems, Inc.,Cryo-Cell... - June 22nd, 2022
- Pricing & Payment Plans | AlphaCord - Newborn Stem Cell Banking - June 20th, 2022
- Global Cholera Vaccine Market Garnered a Revenue of Approximately USD 68 Million in 2021 and Further Touch a CAGR of ~7% During 2022-2030; Market to... - June 20th, 2022
- Global Potash Fertilisers Market To Be Driven By Changing Food Habits Among Customers In The Forecast Period Of 2022-2027 Designer Women - Designer... - June 18th, 2022
- Stem Cell Banking Outsourcing Market 2022 with a CAGR of %, prime firms report covers, business Outlook, In-depth Analysis Business Opportunities and... - June 18th, 2022
- Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 Designer Women - Designer Women - June 15th, 2022
- The age reversal tech that billionaires are banking on - Freethink - June 15th, 2022
- Cord Stem Cell Banking Market Biggest Demand with Growth and Key Players Analysis CBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell... - June 15th, 2022
Recent Comments